Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
Regulatory Filings Classification · 87% confidence The document is a corporate press release announcing a positive CHMP opinion for Sanofi’s drug, including forward‐looking statements and media/investor contacts. It does not present financial results, request votes, or constitute an official regulatory or financial report itself. It’s a general announcement that does not fit other specific categories, making it a fallback Regulatory Filing (RNS).
2026-04-24 English
Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques seconda
Regulatory Filings Classification · 85% confidence The document is a corporate press release (communiqué de presse) announcing the EU CHMP’s positive recommendation for Sanofi’s drug Cenrifki (tolebrutinib). It contains clinical study details and forward-looking statements, but no financial results, no shareholder or board matters, no dividend/share actions, nor any structured financial report. This falls outside all specific financial filing categories and thus defaults to the general Regulatory Filings category (RNS).
2026-04-24 French
6-K - Sanofi (0001121404) (Filer)
Foreign Filer Report
2026-04-23 English
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA
Regulatory Filings
2026-04-23 French
Press Release: Q1 2026: double-digit sales and business EPS growth
Earnings Release Classification · 92% confidence The document is a Sanofi press release announcing Q1 2026 sales, business EPS, pipeline updates, capital allocation, guidance, and highlights of financial performance by geography and segment. It is not the full interim report but an initial earnings announcement with key metrics and commentary. Therefore, it fits the Earnings Release (ER) category. Q1 2026
2026-04-23 English
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique s
Regulatory Filings Classification · 87% confidence The document is a corporate press release (communiqué de presse) announcing FDA approval of Dupixent for a new pediatric indication. It contains no financial statements, no shareholder meeting details, no earnings figures, no board changes, and no regulatory report attachments. It is not a notice of dividend, prospectus, or transaction in shares. As a general corporate announcement with regulatory context (FDA approval), it falls under the Miscellaneous Regulatory Filings category (RNS).
2026-04-22 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.